The healthcare distribution giant is expanding its specialty pharmacy and patient services portfolio through a major cash-and-stock deal valued at $2.25 billion.

Healthcare giant McKesson has purchased Precision Medicine to expand its clinical research and commercialization services, marking a strategic move to strengthen its position in the pharmaceutical supply chain and research sector.

Several corporate executives, including Roku president Fuchsberg and Aehr VP Alistair Sporck, have engaged in significant stock transactions, with some selling millions of dollars in shares while others made purchases. These insider trades, such as Sporck's sale of over $200,000 in company stock, are closely watched by investors.

McKesson, a healthcare company, has provided its fiscal 2027 adjusted EPS guidance, projecting $44.20 to $45.00, and announced plans for $5 billion in share repurchases.

McKesson Corporation (MCK) experienced a slide in its stock performance during the second quarter.

An analysis is provided to determine if McKesson Corporation (MCK) stock is a favorable investment choice at this time.

Analyst reports have been published for McKesson Corp and Avery Dennison Corp, providing insights into their financial performance and market outlook.

An analysis highlights factors that position McKesson Corporation (MCK) as a potentially attractive investment opportunity.

UBS has stated that McKesson’s (MCK) FY27 outlook appears 'good enough' following its fourth-quarter results, providing an analyst perspective on the company's future financial projections.

McKesson has anticipated fiscal 2027 adjusted EPS of $43.80-$44.60 while advancing its Medical-Surgical separation. Separately, UGI forecasts $2.75-$2.90 fiscal 2026 adjusted EPS and is moving forward with a $470 million electric divestiture.

An earnings preview for McKesson outlines key expectations ahead of the company's upcoming financial report.

Evercore ISI has reduced its target for McKesson (MCK) and included the company on its tactical underperform list.

An analyst report concerning McKesson Corp. has been published, offering a detailed assessment of the healthcare company's financial health and market position.

Articles provide analysis on the stock performance of various companies like CVS Health, Trane Technologies, and McKesson Corporation, comparing them to broader market indexes, alongside general market talk and sentiment.

McKesson stock climbed sharply as investors responded favorably to company updates and strengthening demand within the healthcare distribution sector.

Several companies, including Oscar Health, Optimum Communications, and Ormat Technologies, have released highlights from their second-quarter earnings calls. These reports provide updates on their financial performance and business operations for the recent quarter.

Despite strong fundamentals, healthcare stocks are reportedly being overlooked by investors, with analysts recommending several companies including Eli Lilly and McKesson.

McKesson's stock is reportedly shrinking, a development that is presented as an intentional part of the company's strategy.

Barclays has reiterated its 'Overweight' rating on McKesson (MCK), suggesting a positive outlook for the healthcare company's stock.

A market update provides information on the stock performance and relevant news for MCK (McKesson Corporation) and AVGO (Broadcom Inc.).

McKesson Corporation emphasizes the resilience of its core drug distribution network, asserting its ability to withstand challenges over time.

McKesson has released key highlights from its fourth-quarter earnings call, providing insights into its financial results and strategic initiatives.

William Blair has started coverage on McKesson (MCK) with an Outperform rating, citing the company's durable competitive moat.

McKesson Corporation has announced plans to sell approximately a 13% stake in its Medical-Surgical Solutions business to Apollo. This strategic move involves a significant portion of the unit being acquired by the investment firm.

Bank of America has lowered its price target for McKesson (MCK), citing concerns over pricing pressure related to GLP-1 drugs. This adjustment reflects potential challenges for the healthcare company in the current market.

Bank of America has raised its price target for McKesson (MCK) to $1,040, seeing upside potential from the company's biosimilar initiatives.

Barclays has increased its price target for McKesson (MCK), suggesting that the company's shares are likely to remain in favor.

Major healthcare distributor McKesson has finalized its purchase of Precision Medicine Group for $2.25 billion, expanding its portfolio in specialized pharmaceutical and patient support services.

Market experts present mixed outlooks on the healthcare distributor's future performance, weighing sector challenges against operational strengths.

This article offers an earnings preview, detailing what to anticipate from McKesson's financial results for the first quarter of 2027.

McKesson (MCK) showcased its AI-powered tools designed for independent pharmacies at its annual ideaShare Conference, emphasizing technological advancements in the pharmaceutical sector.

Analysts are providing their perspectives and ratings on McKesson Corporation (MCK), a healthcare company, with various financial assessments.

An analysis questions whether McKesson stock is underperforming in comparison to the Dow Jones Industrial Average.

McKesson Corporation (MCK) saw a 50% surge in its stock value, attributed to robust earnings growth and a resilient drug distribution model.

McKesson (MCK) released its earnings transcript for the fourth quarter of 2026, detailing its financial performance.

Several prominent companies, including Cigna, Pfizer, and United Rentals, declared their latest dividend payouts to shareholders, with some announcing regular distributions and one a special dividend.

An analysis examines McKesson stock, describing it as a compounding engine that is currently facing a critical test in the market.

California Governor Gavin Newsom lauded Apple's '50 years of innovation' even as other major companies like Tesla, Chevron, and McKesson have left the state.

McKesson's stock performance is attributed to significant inflows from institutional investors.